Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa open-label single-arm study of OpRegen subretinal delivery in geographic atrophy due to age-related macular degeneration
MOH_2024-04-30_013388Phase 2Recruiting
- Sponsor
- Roche
- Start
- Apr 2024
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of OpRegen in age-related macular degeneration (AMD), sponsored by Roche. Primary endpoints: Success of surgical subretinal delivery of OpRegen and Safety of OpRegen. Started Apr 2024; status: recruiting.
02
Drugs
OpRegen
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on MOH_2024-04-30_013388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-04-30_013388.